نتایج جستجو برای: differentiated thyroid cancer tsh levothyroxine suppressive therapy

تعداد نتایج: 1565626  

Journal: :The Journal of clinical endocrinology and metabolism 2002
Thierry Métayé Emmanuelle Menet Joëlle Guilhot Jean-Louis Kraimps

Most of the TSH effects on the proliferation and differentiation of thyroid cells are mediated by cAMP via an adenylyl cyclase-activating Gs protein. TSH receptor responsiveness in cell cultures, is regulated by G protein-coupled receptor kinase (GRK) 2 and 5. To determine whether an alteration in activity and expression of GRKs might be associated with variable levels of TSH receptor desensiti...

2012
Paweł Gut Magdalena Matysiak-Grześ Jakub Fischbach Aleksandra Klimowicz Maria Gryczyńska Marek Ruchała

Differentiated thyroid cancer is one of the most common endocrine cancers. Typical standard treatment includes total thyroidectomy with partial lymphadenectomy, then depending on the indications, treatment with iodine isotope 131-I. A prerequisite to conduct the therapy is to obtain endogenic thyroid-stimulating hormone (TSH) stimulation (TSH > 30 µU/ml). We describe two patients with different...

2018
Nikolina Zdraveska Maja Zdravkovska Violeta Anastasovska Elena Sukarova-Angelovska Mirjana Kocova

BACKGROUND Diagnostic re-evaluation is important for all patients with congenital hypothyroidism (CH) for determining the etiology and identifying transient CH cases. Our study is a first thyroxine therapy withdrawal study conducted in Macedonian CH patients for a diagnostic re-evaluation. We aimed to evaluate the etiology of CH, the prevalence of transient CH and identify predictive factors fo...

2015
Seo Young Sohn Ji Young Joung Yoon Young Cho Sun Mi Park Sang Man Jin Jae Hoon Chung Sun Wook Kim

BACKGROUND There are limited data about whether patients who receive initial treatment for differentiated thyroid cancer (DTC) gain or lose weight during long-term follow-up under thyroid stimulating hormone (TSH) suppression. This study was aimed to evaluate whether DTC patients under TSH suppression experience long-term weight gain after initial treatment. We also examined the impact of the r...

2018
Charlotte S Schömig Marie-Ève Robinson Julia E von Oettingen

Congenital hypothyroidism requires prompt treatment to prevent adverse health outcomes. Poor intestinal levothyroxine absorption can complicate management. We present a case of a term female newborn with necrotizing enterocolitis (NEC) requiring subtotal ileum resection. Congenital hypothyroidism was diagnosed by newborn screening. Treatment was complicated by intestinal malabsorption of levoth...

2008
SELWYN TAYLOR

Thyroid cancer is a rare disease. Aetiological factors are increased secretion of TSH and exposure of the growing gland to ionizing radiation. Pathological classification is in two main groups: differentiated and undifferentiated. Differentiated is subdivided into papillary, follicular and medullary. Papillary and medullary carcinomas occur in young patients, grow slowly, spread by lymphatics. ...

Journal: :Endocrine-related cancer 2009
Kristien Boelaert

There is mounting evidence that the serum concentration of TSH is an independent predictor for the diagnosis of thyroid malignancy in patients with nodular thyroid disease. Furthermore, preoperative serum TSH concentrations are higher in patients with more aggressive tumours, suggesting a potential role for TSH in the progression of differentiated thyroid cancer. Based on these observations, pa...

2014
Eon Ju Jeon Eui Dal Jung

We want to thank the editors of Endocrinology and Metabolism for giving us the opportunity to publish our work, and have provided the following response to Prof. Jung’s letter. At present, thyroid nodules are common clinical problem. The prevalence of differentiated thyroid cancer (DTC) is dramatically increasing and a large number of clinical studies have been conducted. The American Thyroid A...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2006
J W B de Groot T P Links W T A van der Graaf

A 73-year-old woman was admitted with fatigue, nausea, cold-intolerance, hair-loss, brittle nails, progressive weakness and impressive facial oedema 6 months after starting imatinib (600 mg daily) for metastatic gastrointestinal stromal tumour (GIST, Figure 1) elsewhere. Previously, she had thyroidectomy and I-ablation for follicular thyroid carcinoma. She always had normal thyroid function usi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید